

[HOME](#)[ABOUT](#)[TEAM](#)[PROTOCOL](#)[INSTRUCTIONS](#)[SUBMIT CASES](#)[CONTACT](#)[Home](#) » [Data Entry Management System \(DEMS\)](#)

Data Entry Management System (DEMS)

Case identification

Case ID *

Please assign above a case identification number related to this case submission. Please ensure that you keep this "Case ID" in your records (excel file or any other database) if you would like to access this case in the future and perform changes. For each case there should be a unique ID assigned to it. Please ensure that the "Case ID" does not contain any patient identification information, such as date of birth, hospital number, case number, etc.

Patient characteristics

Recipient gender * Male FemaleRecipient age * yearsRecipient height * cmRecipient weight * kg[Height / weight converter](#)Donor age yearsLab MELD at time of liver transplantation * points[MELD Score Calculator](#)

Account

[My account](#)[Log out](#)

Documents

[Protocol](#)[Instructions](#)[Case report form in PDF](#)

Case Report Form

[Submit cases](#)[My submitted cases](#)[Height/ weight converter](#)[Clavien Dindo Classification](#)[Date duration calculator](#)[Lab unit converter](#)

Life support prior to transplantation *

	Yes	No	Unknown
Dialysis prior to transplantation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ventilation prior to transplantation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vasopressors prior to transplantation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Retransplantation * Yes No

Retransplantation indicates prior liver transplantation(s)

Underlying liver disease (multiple options): *

	Yes	No	Unknown
Non-alcoholic steatohepatitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hepatitis B virus infection	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hepatitis C virus infection	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Alcohol	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Autoimmune hepatitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Wilson's disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If other underlying liver disease, please indicate

Indication for transplantation (multiple options): *

	Yes	No	Unknown
Acute liver failure	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hepatocellular carcinoma	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cholangiocarcinoma	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Other	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-------	-----------------------	-----------------------	-----------------------

If other indication for liver transplantation, please indicate

TACE prior to transplantation Yes No

Radiation prior to transplantation Yes No

Direct to the liver, for example for cholangiocarcinoma.

Comorbidities *

	Yes	No	Unknown
Coronary artery disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Stroke prior to transplant	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Smoker	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Valvular heart disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Heart arrhythmias	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hypertension	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cerebrovascular disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hypercoagulation disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Dyslipidemia	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Diabetes mellitus	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Stroke	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Smoker	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sepsis / septic shock	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If other comorbidities, please indicate

Anticoagulation prior to transplantation (multiple options): *

	Yes	No	Unknown
Antiplatelet agents	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Anticoagulant agents	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If yes, please indicate which medications:

E.g. Antiplatelet agents: Aspirin, Clopidogrel (Plavix). Anticoagulant agents: Phenprocoumon (Marcoumar), Warfarin (Coumadin), Rivaroxaban (Xarelto), Heparin, Heparin (Liquemin), Dabigatran (Pradaxa), Apixaban (Eliquis), Edoxaban (Savaysa), Enoxaparin (Lovenox), Fondaparinux (Arixtra), etc.

Operation characteristics

Graft type * DBD DCD

DBD indicates donor after brain death. DCD indicates donor after cardiac death

Simultaneous kidney transplantation * Yes No

Cold ischemia time * minutes


Operation duration * minutes

Use of veno-venous bypass * Yes No

Operation technique * Classic Piggy-bag

Number of arterial anastomoses *

Donor anatomy type * 1 2 3 4 5



Donor Anatomy according to Hiatt, Gabbay and Busuttil (Ann Surg July 1994):
 Dotted lines indicate that the variant artery may be accessory (if branch shown by dotted line is present) or replaced (if absent). Type 1: normal. Type 2: replaced (accessory) left hepatic artery from left gastric. Type 3: replaced (accessory right hepatic artery from SMA. Type 4: double replaced system. Type 5: common hepatic artery from SMA.

Arterial flow measurement intraoperatively ml/min


Type of arterial conduit used * Allograft Prosthetic

If allograft conduit used, which vessel?


If prosthetic conduit used, which type?

Placement of conduit *


Infrarenal



Supraceliac



Iliacal



If other placement, please indicate

Reason for need of conduit *

If other reason for need of conduit, please indicate

Additional arterial back-table reconstructions? * Yes No

Biliary reconstruction *

Intraoperative blood product administration *

	Yes	No	Unknown
Intraoperative fresh-frozen Plasma (FFP)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intraoperative red blood cells (RBC)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intraoperative platelets (Plt)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If FFP, how many units? units

If RBC, how many units? units

If Plt, how many units? units

Medications post transplantation

Immunosuppression post transplantation

Immunosuppression post transplantation (multiple options) *

- Azathioprine
- Corticosteroids
- Cyclosporine
- Everolimus
- Mycophenolate
- Sirolimus
- Tacrolimus
- Other
- None

If other immunosuppression therapy, please indicate

Anticoagulation post transplantation

Anticoagulation post transplantation (multiple options): *

	Yes	No	Unknown
Antiplatelet agents	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Anticoagulant agents	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If yes, please indicate which medications:

E.g. Antiplatelet agents: Aspirin, Clopidogrel (Plavix). Anticoagulant agents: Phenprocoumon (Marcoumar), Warfarin (Coumadin), Rivaroxaban (Xarelto), Heparin, Heparin (Liquemin), Dabigatran (Pradaxa), Apixaban (Eliquis), Edoxaban (Savaysa), Enoxaparin (Lovenox), Fondaparinux (Arixtra), etc.

If anticoagulation, please indicate target therapy Prophylactic Therapeutic

Prophylactic therapy means 10000 or 15000 IU heparin per day for example. Therapeutic therapy means according to aPTT or Anti-Xa activity for heparin at therapeutic levels (usually over 20000 heparin)

Posttransplantation outcome

Lab values

Peak AST (up to 7th post-TPL day) * (U/l)

Peak ALT (up to 7th post-TPL day) * (U/l)

Bilirubin at 7th post-TPL day * $\mu\text{mol/l}$ (SI)
 Typical normal ranges 3-25 ($\mu\text{mol/l}$) (SI)

INR at 7th post-TPL day * ratio
 Typical normal ranges 3-25 ($\mu\text{mol/l}$) (SI)

Lab unit converter

Clavien-Dindo Classification of Postoperative Complications within 90 days post-TPL *

	None	1	2	3a	3b	4a	4b	5 (death)
Biliary	<input type="radio"/>							
Bleeding	<input type="radio"/>							
Graft related	<input type="radio"/>							
Hemodynamic	<input type="radio"/>							
Infections	<input type="radio"/>							
Neurologic	<input type="radio"/>							
Renal	<input type="radio"/>							
Respiratory	<input type="radio"/>							
Vascular	<input type="radio"/>							
Other A	<input type="radio"/>							
Other B	<input type="radio"/>							
Other C	<input type="radio"/>							

Please indicate all different types of complications and their grades according to the Clavien-Dindo Classification from transplantation until the 90th posttransplantation day. If the recipient did not encounter any complications from operation until discharge, please indicate "None" for all types and grades of complications.

If biliary complication, indicate type

If vascular complication, indicate type

If graft related complication, indicate type

If there were any other types of complications encountered, please describe them

below:

Clavien-Dindo Classification

Length of ICU stay * days

In case of readmission(s) to the Intensive Care Unit (ICU), please indicate the total number of ICU stay in days above.

Length of hospital stay * days

Readmission within 90 days from transplantation * Yes No

If yes, what was the reason for readmission?

Arterial patency from transplantation until last follow up or death

Occlusion indicates total occlusion while stenosis indicates partial occlusion.

Arterial occlusion / stenosis - First occasion

Occlusion indicates total occlusion while stenosis indicates partial occlusion.

Arterial occlusion / stenosis *

If yes, days from transplantation to arterial occlusion / stenosis

days

If stenosis (partial occlusion), please indicate the reason

First Intervention type (multiple options):

- Percutaneous transluminal angioplasty (PTA)
- Stent
- Thrombolytic therapy
- Redo of the anastomosis
- Redo of the conduit
- Other

If yes, patency rescue by this intervention Yes No

Yes indicates that after the intervention, the artery remained opened, thus rescued by the intervention. No means that the intervention was unsuccessful.

Second occasion - Arterial reocclusion / restenosis

Occlusion indicates total occlusion while stenosis indicates partial occlusion.

Arterial reocclusion / restenosis *

If yes, days from first occlusion to reocclusion

days

Occlusion contains also clinically relevant stenosis (i.e. partial occlusion)

If restenosis (partial occlusion), please indicate the reason

Reintervention type (multiple options):

- Percutaneous transluminal angioplasty (PTA)
- Stent
- Thrombolytic therapy
- Redo of the anastomosis
- Redo of the conduit
- Other

If yes, patency rescue by reintervention Yes No

Yes indicates that after the intervention, the artery remained opened, thus rescued by the intervention. No means that the intervention was unsuccessful.

Third occasion - Arterial re-reocclusion / re-restenosis

Occlusion indicates total occlusion while stenosis indicates partial occlusion.

Arterial re-reocclusion / re-restenosis *

If yes, days from reocclusion to re-reocclusion

days

Occlusion contains also clinically relevant stenosis (i.e. partial occlusion). This duration in days indicates the time from second to third occlusion.

If re-restenosis (partial occlusion), please indicate the reason

Re-reintervention type (multiple options):

- Percutaneous transluminal angioplasty (PTA)
- Stent
- Thrombolytic therapy
- Redo of the anastomosis
- Redo of the conduit
- Other

If yes, patency rescue by re-reintervention Yes No

Yes indicates that after the intervention, the artery remained opened, thus rescued by the intervention. No means that the intervention was unsuccessful.

Survival

Patient status * Alive Dead

The patient status indicates whether the patient was last seen alive or dead at the hospital, followed up at the outpatient clinic, family doctor, or confirmed after being contacted by phone. Below you are requested to indicate the number of days from transplantation until last follow up or death.

Days from transplantation to last follow up or death *

days

i.e. days from transplantation to death or last follow up recording. This value (number of days) may indicate the time from transplantation to the last follow up recording for alive patients or the time from transplantation to death for those that died.

Graft status * Graft functioning Graft failure

Graft failure indicates retransplantation or patient death.

Days from transplantation to last follow up or graft failure *

days

The graft status should be calculated from the date of transplantation to the date of retransplantation or death. If the graft was functioning at the last follow up, please indicate the days from transplantation until last follow up.

Comments (optional)

Submit

Platform

[Home](#)
[About](#)
[Team](#)

Data Entry

[Protocol](#)
[Instructions](#)
[Submit cases](#)

Contact us

[Prof Henrik Petrowsky](#)
[Dr Christian Oberkofler](#)
[Dr Dimitri Raptis](#)

Headquarters

[University Hospital Zurich](#)
[Rämistrasse 100](#)
[8091 Zurich, Switzerland](#)

© 2017 conduit4OLT.org. All Rights Reserved.

Design by [Dimitri Raptis](#)